5 November 2015 - It looks like children and adolescents with neuroblastoma will not be able to access United Therapeutics’ Unituxin (dinutuximab) on the NHS, after NICE deemed the drug too expensive.

For more details, go to: http://www.nice.org.uk/guidance/indevelopment/gid-tag507/consultation/html-content